ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ATHX Athersys Inc

0.1018
0.00 (0.00%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Athersys Inc NASDAQ:ATHX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1018 0.101 0.104 0 01:00:00

Athersys to Host Third Quarter Financial Results Call

14/10/2019 6:00pm

GlobeNewswire Inc.


Athersys (NASDAQ:ATHX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Athersys Charts.

Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2019 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 6, 2019, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:

DateNovember 6, 2019
Time4:30 p.m. (Eastern Time)
Telephone access: US and Canada(877) 396-3286
Telephone access: International(647) 689-5528
Conference ID:4183148
Live webcastwww.athersys.com under Investors section

We encourage shareholders to listen using the webcast link and to use the phone line if you intend to ask a question. A replay will be available on the webcast at www.athersys.com under the investors section approximately two hours after the call has ended. Shareholders may also call in for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on November 13, 2019 by dialing (800) 585-8367 or (416) 621-4642 and entering conference ID: 4183148.

About Athersys

Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and cardiovascular disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com.

Contacts:

William (B.J.) Lehmann, J.D.                          President and Chief Operating Officer                                              Tel: (216) 431-9900                                            bjlehmann@athersys.com 

Karen Hunady Director of Corporate Communications and Investor RelationsTel: (216) 431-9900khunady@athersys.com

David Schull                 Russo Partners, LLCTel: (212) 845-4271 or (858) 717-2310David.schull@russopartnersllc.com

1 Year Athersys Chart

1 Year Athersys Chart

1 Month Athersys Chart

1 Month Athersys Chart

Your Recent History

Delayed Upgrade Clock